Hypertension and Blood Pressure Dysregulation in Cancer Survivors: Mechanisms, Management, and Future Directions

Scritto il 10/11/2026
da Lauren Daniel

Curr Hypertens Rep. 2026 Nov 10;28(1):49. doi: 10.1007/s11906-026-01394-3.

ABSTRACT

PURPOSE OF REVIEW: This review examines the epidemiology, mechanisms, and management of hypertension in patients with cancer, emphasizing treatment-related hypertension, autonomic dysfunction, blood pressure lability, and evolving blood pressure targets in cardio-oncology.

RECENT FINDINGS: Among cancer survivors both during and after their cancer treatment, hypertension is highly prevalent and is associated with increased cardiovascular morbidity and mortality. Vascular endothelial growth factor (VEGF) inhibitors are one of the most common causes of cancer treatment-induced hypertension, although other cancer treatments also contribute. Emerging evidence highlights the coexistence of orthostatic hypotension and hypertension, likely related to autonomic dysfunction, arterial stiffening, baroreflex impairment, and endothelial dysfunction related to cancer and its treatment. Medical management, intensive blood pressure control, and cardio-oncology rehabilitation may improve blood pressure control while mitigating adverse outcomes. Current hypertension management in cancer survivors largely follows general population guidelines despite the unique pathophysiology of cancer and its therapies. Future research should establish cancer-specific blood pressure targets, optimize antihypertensive strategies, and further investigate management of blood pressure lability, autonomic dysfunction, and cardio-oncology rehabilitation.

PMID:43007571 | PMC:PMC13751569 | DOI:10.1007/s11906-026-01394-3